Portal de Periódicos da CAPES

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study

2016; Elsevier BV; Volume: 98; Linguagem: Inglês

10.1016/j.lungcan.2016.05.016

1872-8332

I. Monnet, Clarisse Audigier-Valette, Nicolas Girard, A. Vergnenègre, Olivier Molinier, Pierre Jean Souquet, F Blanchon, Franck Bonnetain, Naila Taguieva-Pioger, Corinne Lamour, Marie Wislez,

Lung Cancer Research Studies

Highlights•Data on erlotinib use in metastatic squamous NSCLC are limited.•Pepita is a prospective cohort on 2nd-line erlotinib in 152 squamous NSCLC patients.•Median progression free survival was 3 months and overall survival 5.8 months.•No unexpected safety issues were noted.•Erlotinib 2nd-line treatment may be a valuable option in metastatic squamous NSCLC.AbstractObjectivesErlotinib, an inhibitor of tyrosine kinase activity of the epidermal growth factor receptor, is effective in non-small cell lung cancer (NSCLC). Data on erlotinib use in squamous NSCLC are limited. This observational study aimed at evaluating the efficacy and safety of second-line erlotinib in patients with stage IIIB/IV squamous NSCLC in a real-life setting.Material and methodsPatients with predominantly squamous stage IIIB/IV NSCLC, who failed first-line platinum-based therapy, were recruited and followed-up for 12 months. Patients underwent visits each trimester. Data were derived from case report forms, and functional assessment of cancer therapy-lung (FACT-L) questionnaires.ResultsA total of 152 patients were enrolled; the majority were males (90%) and mean age was 67.7 years. All patients had squamous (97%) or predominantly squamous (3%) NSCLC, of stage IIIB (21%) or IV (79%). Median progression free survival (PFS) and overall survival were 3 and 5.8 months, respectively. Disease progression was observed in the majority of the patients, mostly due to progression of primary tumour and/or metastatic sites, and led to death in 91/107 of patients. Of the 107 deaths reported, none were due to erlotinib. FACT-L questionnaires were interpretable up to the first visit and were in line with PFS data, showing a relatively good quality of life up to Month 3 (mean total score=78.8). No new or unexpected safety issues were reported.ConclusionsThe results of this real-life cohort study like those of previous phase III/IV subgroups study analyses indicate that erlotinib is a valuable option for second-line treatment of stage IIIB/IV squamous NSCLC.